Intertek Joins IPAC-RS to Help Drive Innovation in Inhaled Medicines
10 Jan 2024
Melbourn, Cambridge, UK: Intertek (the “Group” or “Company”), a Total Quality Assurance provider to industries worldwide, is pleased to announce it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), marking a significant milestone in the Group’s commitment to advancing science, regulatory frameworks, and innovation for inhaled and nasal medicines.
For over 30 years, Intertek has remained dedicated to supporting enhanced patient outcomes through excellence in Good Manufacturing Practice (GMP) and Chemistry, Manufacturing, and Controls (CMC) laboratory services. The Company actively contributes to the future of orally inhaled and nasal drug products (OINDPs) through its Science-based Customer Excellence approach and has established a Centre of Excellence for the development of these products at its Cambridge, UK, campus. This site includes a dedicated biologics suite focusing on the development of complex large molecule drug products for respiratory delivery including proteins, antibodies, DNA medicines, vaccines, and gene therapies. Intertek is also host of the sector’s first forum on inhaled and nasal biologics and DNA medicine development and the 3rd edition of this conference will take place 26-27 September 2024.
Inhaled delivery routes for treating respiratory diseases offer targeted delivery to the lungs, potentially unlocking novel treatment pathways and improved pharmacokinetics. Intertek’s membership of IPAC-RS highlights its commitment to supporting the development of safe, effective, and innovative drug products.
IPAC-RS is a global industry association dedicated to advancing the science and regulatory aspects of orally inhaled and nasal drug products (OINDPs) through data collection, analysis, and joint research and development projects. IPAC-RS aims to foster consensus and contribute to effective regulations and standards by sharing research results through various platforms such as conferences, technical journals, webinars, and discussions with regulatory bodies.
Chris Vernall, Intertek Commercial Director, commented: “IPAC-RS plays an essential role in building the OINDP community and contributing to the advancement of regulatory science for orally inhaled and nasal drug products. Joining IPAC-RS is a fantastic opportunity to share cross-industry understanding on a range of scientific and regulatory topics, and to contribute to the evolving area of inhaled biologics and DNA medicine development, with a common objective of better patient outcomes.”
Ashleigh Wake, Intertek Pharmaceutical Services Director, UK, and Switzerland highlighted: “As part of our commitment to giving customers the Intertek Science-based Total Quality Assurance advantage to strengthen their businesses, we are focused on progressing inhaled and nasal drug product innovation, as well as supporting the development of safer, and more effective medicines. We are delighted to be a part of IPAC-RS and look forward to collaborating with our fellow members in this important organization.”
Mike Needham, IPAC-RS Chair, commented: “IPAC-RS has greatly benefitted from the contributions and commitment of its Associate Members and warmly welcomes Intertek as an Associate Member. We look forward to Intertek’s active engagement and collaboration in the consortium’s scientific and regulatory initiatives.”
Intertek’s pharmaceutical services locations include Melbourn, Cambridge (UK), Manchester (UK), Basel (Switzerland), Whitehouse, (New Jersey, USA), Mumbai (India) and Melbourne, (Australia). Through integrated expertise in analytical and formulation support for the pharmaceutical, biotechnology and drug delivery industries, Intertek helps clients to meet milestones for their challenging pharmaceutical development programs through systemic, end-to-end Total Quality Assurance solutions.
For Media Information
Please contact:
Lorna Kettle
ECA Marketing Director, Intertek Pharmaceutical Services
T: +44 (0) 116 296 1620
E: lorna.kettle@intertek.com
About IPAC-RS
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) has been the leading global voice of the orally inhaled and nasal drug products (OINDP) industry for close to 25 years. Through joint research, benchmarking, collecting and analyzing data, and developing best practices, IPAC-RS advances and supports science-based regulatory approaches for OINDP, to ensure their availability, safety, efficacy and quality. IPAC-RS works collaboratively across the industry and with external experts from regulatory agencies, standard-setting bodies, academia, pharmacopeias, healthcare providers, patient groups, and other stakeholders. IPAC-RS members are based around the world, and their activities are global, with region-specific projects in North and South America, Europe, and Asia. IPAC-RS shares its findings with the larger scientific and regulatory community through publications, online tutorials, in-person training courses, webinars, and conferences. www.ipacrs.org https://www.linkedin.com/company/ipacrs
About Intertek
TOTAL QUALITY. ASSURED.
Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers’ operations and supply chains. Intertek Total Quality Assurance expertise, delivered consistently with precision, pace and passion, enabling our customers to power ahead safely.
Inhalation Drug Development Services
Inhalation Drug Product Development Services
Pharmaceutical Services
Pharmaceutical services to overcome the challenges of biologic and small molecule drug development and manufacturing.